TriSalus Life Sciences reported second quarter 2026 financial results, generating $11.4 million in revenue and maintaining full-year guidance of $54 million to $57 million. The company expanded its commercial organization and raised $46.0 million in gross proceeds from an equity offering in the first quarter, ending Q2 with $46.3 million in cash. Operating losses widened to $9.8 million due to increased sales and marketing expenses, while net loss was $9.2 million, or $0.16 per share. TriSalus is an oncology-focused medical technology company that integrates novel drug delivery devices with standard-of-care therapies and investigational immunotherapeutics for solid tumors.